COUNCIL MEETING Sharing Our Passion For Life

Health Policy, Advocacy & HCT: What TC's Need to Know in 2018

Alicia Silver, MPP & Kristen Bostrom November 11, 2017

BESSTHE MATCH COUNCIL MEETING: Sharing Our Passion For Life

Disclosures

The following faculty and planning committee staff have no financial disclosures:

Name	Institution
Alicia Silver, MPP	NMDP/Be The Match
Kristen Bostrom	NMDP/Be The Match
Susan Leppke	NMDP/Be The Match

Learning objectives

At the conclusion of this session, attendees will be able to:

- Learning objective 1: Describe the current status of Medicare coverage and reimbursement for HCT
- Learning objective 2: Explain NMDP's advocacy approach for expanded Medicare coverage and enhanced reimbursement
- Learning objective 3: Find resources on the Reimbursement Resource Center for future reference.

Current PPP Priorities




Communication to our Network



COVERAGE



Medicare Coverage



Current CEDs

Myelodysplastic	
Syndromes	

- Opened in 2010
- NCT #01166009

• Opened in 2016

Sickle Cell Disease


Myelofibrosis

Multiple

Myeloma


- aka BMT CTN 1503 (STRIDE2)
 NCT #02766465
- Opened in 2016
 - NCT #02934477
 - Opened in 2016
 - NCT #03127761


MDS CED: Access to Transplant



1896 Allogeneic Transplants Facilitated Through MDS CED since 2010


Medicare Coverage: Lymphoma





Medicare Coverage: Lymphoma

2015 Financial Barriers to HCT Survey: "Does your program transplant Medicare patients who have a disease indication that is not listed on the National Coverage Determination (NCD) and therefore have unknown reimbursement?" (n=56)



Commercial Payer Coverage Lymphoma



BE SETHE MATCH COUNCIL MEETING: Sharing Our Passion For Life

MARROW DONOR PROGRAM

Medicare Coverage Lymphoma: Strategy

MAC approach

Autologous C-APC

Current Reimbursement

NATIONAL MARROW DONOR PROGRAM[®]



CPT 38208 Transplant prep of HPC,

Autologous C-APC

Autologous C-APC Advocacy

- Mini MS-DRG in the OPPS
- Request to be submitted by end of CY

MLN Matters

MLN Matters® Number: SE1624 Re

Related Change Request Number: N/A

Types of Stem Cell Transplants that are covered:

Medicare covers allogeneic and autologous transplants. Allogeneic and autologous stem cell transplants are covered under Medicare for specific diagnoses.

1. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Allogeneic stem cell transplantation is a procedure in which a portion of a healthy donor's stem cells is obtained and prepared for intravenous infusion to restore normal hematopoietic function in recipients having an inherited or acquired hematopoietic deficiency or defect.

Expenses incurred by a donor are a covered benefit to the recipient/beneficiary but, except for physician services, are not paid separately. Services to the donor include physician services, hospital care in connection with screening the stem cell, and ordinary follow-up care.

2. Autologous Stem Cell Transplantation (AuSCT)


Autologous stem cell transplantation is a technique for restoring stem cells using the patient's own previously stored cells. Autologous stem cell transplants (AuSCT) must be used to effect hematopoietic reconstitution following severely myelotoxic doses of chemotherapy (High Dose Chemotherapy (HDCT)) and/or radiotherapy used to treat various malignancies.

In their February 2016 OIG report, the OIG determined that Medicare paid for many stem cell transplant procedures incorrectly. The main finding was that providers billed these procedures as inpatient when they should have been submitted as outpatient or outpatient with observation services. The key points in the report include:

- According to an independent medical review contractor contracted by OIG for this report, stem cell transplants are routinely performed in the outpatient setting.
- Hospitals may have incorrectly thought that stem cell transplantation was on CMS's list of inpatient-only procedures.

MARROW DONOR PROGRAM

Health Economics



Sickle Cell Disease (SCD)

Overview of Medicaid & SCD initiative

REIMBURSEMENT



Cost of Allogeneic HCT

Majhail et al.

- Total median <u>cost</u> \$203,026
- Includes inpatient and outpatient costs

MARROW DONOR PROGRAM BE 🚼 THE MATCH"

Milliman 2017

- Estimated billed <u>charges</u> \$892,700
- 30 days pre-tx, cell procurement, inpatient, 180 days post-tx and drugs (immunosuppressant's, etc.)

NMDP Costs


- Average marrow/PBSC: \$65,117
- Average cord blood: \$48,436

Medicare Allogeneic Transplant Trends

Cell Source Mix Medicare Patient Volume 28% 68% Marrow/PBSC Related Cord Blood



Current Medicare Reimbursement



BESS THE MATCH' COUNCIL MEETING: Sharing Our Passion For Life

NATIONAL MARROW DONOR PROGRAM[®]

Medicare Reimbursement Challenges

Persistent Issues with Reporting Costs

Data Year	Provider	% Reporting Revenue Code 0815	Minimum Revenue Code 0815 Charge	Mean Revenue Code 0815 Charge	Maximum Revenue Code 0815 Charge
2016	Non-ADCC	75%	\$416 (\$138)**	\$72,306 (\$24,005)**	\$422,408 (\$140,239)**
2016	ADCC*	69%	\$2,823	\$67,627	\$214,020

*ADCC data not used in Medicare rate-setting

**Applies the Blood and Blood Products CCR of .332

Medicare Reimbursement Challenges

What if CMS only uses claims with revenue code 0815 in rate-setting?



Medicare Reimbursement Challenges

Donor Source Codes

Providers Reporting		g after 00.91/00.92 12.8079		Weight 12.8079	\$76,847
		New Related MS-DRG	Weight 10.4785	\$62,871	
71%		New Unrelated MS-DRG	Weight 11.6003	\$69,601	



MARROW DONOR PROGRAM

Medicare Reimbursement


MS-DRG Modeling for SAC

Remove Revenue Code 0815 from MS-DRG 014	9.7107	\$58,264
New Unrelated MS-DRG without Revenue Code 0815	9.6931	\$58,158
New Related MS-DRG without Revenue Code 0815	9.7562	\$58,537

Medicare Reimbursement

Best Case Scenario

NATIONAL MARROW DONOR PROGRAM[®]



Medicare Reimbursement



Remember to include **both** <u>revenue</u> <u>code 0815</u> & <u>donor source codes</u> on all allogeneic HCT claims!

CODING & BILLING



NEW ICD-10 PCS Crosswalk!

NATIONAL MARROW DONOR PROGRAM

ICD-10-PCS Codes

ICD-9-CM	2016 ICD-10- PCS	2016-ICD-10-PCS Description	2017 ICD-10- PCS	2017 ICD-10-PCS Description		
Transplant						
	30230G0	Peripheral vein, open, bone marrow, autologous				
41.01	30233G0	Peripheral vein, percutaneous, bone marrow, autologous	1			
Autologous bone marrow transplant	30240G0	Central vein, open, bone marrow, autologous	-			
without purging	30243G0	Central vein, percutaneous, bone marrow, autologous	No Change from 2016			
41.09	30250G0	Peripheral artery, open, bone marrow, autologous				
Autologous bone	30253G0	Peripheral artery, percutaneous, bone marrow, autologous	1			
marrow transplant with purging	30260G0	Central artery, open, bone marrow, autologous	1			
	30263G0	Central artery, percutaneous, bone marrow, autologous	1			
	30230G1	Peripheral vein, open, bone marrow, nonautologous	30230G2	Peripheral vein, open, bone marrow, allogeneic, related		
			30230G3	Peripheral vein, open, bone marrow, allogeneic unrelated		
			30230G4	Peripheral vein, open, bone marrow, allogeneic, unspecified		
	30233G1	Peripheral vein, percutaneous, bone marrow, nonautologous	30233G2	Peripheral vein, percutaneous, bone marrow, allogeneic, related		
			30233G3	Peripheral vein, percutaneous, bone marrow, allogeneic, unrelated		
			30233G4	Peripheral vein, percutaneous, bone marrow, allogeneic, unspecified		
	30240G1	Central vein, open, bone marrow, nonautologous	30240G2	Central vein, open, bone marrow, allogeneic, related		
41.02 Allogeneic bone marrow transplant with			30240G3	Central vein, open, bone marrow, allogeneic, unrelated		
purging			30240G4	Central vein, open, bone marrow, allogeneic, unspecified		
41.03 Allogeneic bone marrow transplant without purging	30243G1	Central vein, percutaneous, bone marrow, nonautologous	30243G2	Central vein, percutaneous, bone marrow, allogeneic, related		
			30243G3	Central vein, percutaneous, bone marrow, allogeneic, unrelated		
			30243G4	Central vein, percutaneous, bone marrow, allogeneic, unspecified		
	30250G1	Peripheral artery, open, bone marrow, nonautologous				
	30253G1	Peripheral artery, percutaneous, bone marrow, nonautologous	N	No Change from 2016		
	30260G1	Central artery, open, bone marrow, nonautologous	No Change from 2016			
	30263G1	Central artery, percutaneous, bone marrow, nonautologous				
	30230Y0	Peripheral vein, open, stem cells, hematopoietic, autologous				
	30233Y0	Peripheral vein, percutaneous, stem cells, hematopoietic, autologous				



COUNCIL MEETING: Sharing Our Passion For Life

AUG 2017 🚃

NEW Donation Process Coding & Billing Guide



Donation Process Coding and Billing Guide

The hematopoietic stem cell donation process from a coding and billing perspective is separated into three phases: donor search, donor work-up, and the collection process. Each phases is described below, as well as detailed coding and billing instructions including cell boost cases.

Donor Search Phase

In this phase, the transplant center (TC) searches for a donor. If an unrelated potential donor(s) is identified, the TC requests confirmatory typing (CT) and infectious disease marker testing (IDM) for the identified donor(s). Requested potential donors are contacted by the donor center (DC) and sent to a testing lab to draw blood. One set of blood tubes are sent to the TC's contracted HLA lab and the other tubes are sent to a contracted IDM lab with an IDM kit for IDM testing. Once the TC has received the HLA CT lab results for all potential donors, they select the donor(s) who will move forward to work-up. In rare cases, TCS may request work-up for more than one potential donor.

This phase ends when the donor(s) are chosen and work-up is requested.

Search Codes

The blood draw is to be sent to an HLA lab for testing.

Service	CPT	CPT Description
Confirmatory Testing (CT) Blood Sample	36415	Collection of venous blood by venipuncture

An IDM kit is sent to the contracted lab.

Service	СРТ	CPT Description
Infectious Disease Marker	86592	Syphilis test – non-treponemal antibody; qualitative (e.g. VDRL, RPR, ART)
(IDM) Testing at	86644	Cytomegalovirus (CMV)
8 8 8 8	86703	HIV-1 and HIV-2 single result
	86704	Hep b core antibody (HBcAb), total
	86790	Virus, not elsewhere specified (HTLV I/II Antibody)
	86803	Hepatitis C Antibody
	86900	Blood typing; ABO
	86901	Blood typing; Rh (D)
	87340	Hepatitis B surface antigen (HBsAg)

COUNCIL MEETING: Sharing Our Passion For Life

CAR-T Coding & Billing

ASBMT led development of new ICD-10 PCS codes, effective October 1, 2017

XW033C3: New Technology, Introduction via <u>Peripheral Vein</u>; Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy

XW043C3: New Technology, Introduction via <u>Central Vein</u>; Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy





ADVOCACY & GRASSROOTS



What is Advocacy?

- Advocacy is any action that aims to influence decisions or supports/defends a cause.
- The term "advocacy" encompasses a broad range of activities used to influence public policies.
- Effective advocacy is one of the best ways to influence public policies and laws.

MARROW DONOR



Why is Advocacy Important?

- Many legislative changes in healthcare impacting pharmaceuticals, doctors, hospitals and the patients we serve
- Members of Congress are overwhelmed so many issues, so little time
- Offices rely on YOU for information on what's important

MARROW DONOR PROGRAM

CIVIC ENGAGEMENT MOMENTUM



67% more advocates taking action

3000% more people have called lawmakers



559% more messages to lawmakers



300% increase in Facebook and Twitter sharing of advocacy campaigns

LAWMAKERS ON SOCIAL MEDIA



What Can **YOU** Do to Help Your Patients?



MARROW DONOR PROGRAM

We Couldn't Do It Without YOU!













Advocate Profiles

Navneet Majhail, MD

Cleveland Clinic

- IPPS & OPPS Comment
 Letters
- Appropriations Take
 Action
- Washington DC Hill Days
- Opinion Editorial (OpEd) signatory



MARROW DONOR PROGRAM



Rocky Billups

Sarah Cannon

- IPPS & OPPS Comment Letters
- Medicare Reimbursement
 Washington DC Hill Day

Sam Sharf

NC Hospitals Chapel Hill

- IPPS & OPPS Comment Letters
- Medicare Reimbursement Washington DC Hill Day
- Opinion Editorial (OpEd) signatory



Congress Working With You



Rep. Gus Michael Bilirakis (R-FL-12)



Rep. Doris Okada Matsui (D-CA-06)

MARROW DONOR Hosts Briefings for NMDP to Educate Members of Congress and their staff

Created in 2015

•

•

Dear Colleague Letters to ask other Members of Congress to join them in support or participation

CONGRESSIONAL CAUCUS to CONGRESSIONAL CAUCUS

Take Action

Stay up-to-date by joining the Advocacy Action Network.

BeTheMatch.org/Advocacy



Several Members of Congress are disappointed with the fact that CMS has not

You can help tool it is important that all Members of Congress understand the importance of fixing this problem and protecting access to transplant. Please contact your Members of Congress today. Urge them to support this soon-hobe introduced

legisation to reform Medicare payment policy bone marrow, peripheral blood stem

22

Several memoters or Congress are used pointed with the excitation of Constants from resolved this problem, and are planning to introduce legislation this fall. The legislation would require CMS to align reimbursement for acquiring cells for stem cell transplant with that of acquiring solid organs. We support these efforts to protect

Protect Access to Care for Medicare Beneficiaries

Exist rith month, the Creters for Madice 4 Madical Services (CAS) sixed the Tradition of the Propective Payment System (PP's) Final Madical Services (Casenders Frageatering adequate payment to transplate carterins who adequate payment to transplate cartering and transplating to Medicare patients. Lewrog an executive interflowater (Fale pages threadens the ability of Medicare patients to medicare patients and transplate transplating the adequate patients to the addition of the security interflowater (Fale pages threadens the ability of Medicare patients to the addition of the addition of the addition of the addition of the security interflowater (Fale pages threadens the ability of Medicare patients to the addition of the security interflowater (Fale pages the transplate the addition of the addition of the security interflowater (Fale pages the transplate the addition of the

patient access.

MARROW DONOR PROGRAM cell and cord blood transplants

BE THE MATCH

support this effort and am ready to Act Nowl

I am a Healthcare Professional ready to Act Nowl

am a Donor/Registry Member ready to Art Now



Can't get enough HCT policy information?

Subscribe to our monthly Reimbursement eNews

Contact Us: payerpolicy@nmdp.org



BE O THE MATCH

COUNCIL MEETING: Sharing Our Passion For Life

Contact Us:

Questions?





THANK YOU!

Alicia Silver <u>alicia.silver@nmdp.org</u> Kristen Bostrom <u>kbostrom@nmdp.org</u>



Evaluation Reminder

Please complete the Council Meeting 2017 evaluation in order to receive continuing education credits and to provide suggestions for future topics.

We appreciate your feedback!